MAY 15, 2018 6:14 PM PDT

A Cure for The Common Cold?

WRITTEN BY: Nouran Amin

Treating the common cold has never been simple and finding effective options has baffled scientists for centuries.

The common cold is caused, for the most part, by the rhinovirus. Getting infected by the Rhinovirus is as easy as one, two, three since common places of infection include home, school, and the workplace. Unfortunately, many attempts to inhibit the actions of the rhinovirus through the implementation of vaccination and antiviral drugs have been proven to be unsuccessful. The primary reason is that the rhinovirus returns in many forms that can rapidly mutate and thus increasing its ability to be resistant to drug treatments.

However, now researchers believe they can develop new ways to nobble the Rhinovirus which will especially advantageous to those individuals with conditions such as asthma and cystic fibrosis, where a simple cold is a threatening health risk. One of those ways includes producing a drug that will interact with one of the enzymatic molecule that can make it a challenge for the Rhinovirus to become drug-resistant.

Robert Soalri, a co-author of this study and a visiting professor at the National Heart and Lung Insitute from the Imperial College of London, explains that “Viruses hijack the host to make more copies of themselves. This enzyme is one of the host enzymes that the virus hijacks".

The researchers observed molecules that interact with a form of a human enzyme that attaches a fatty acid molecule on to proteins. They found that two of these observed molecules independently had little effect on the studied enzyme, but when these molecules were bounded together they developed a striking potency in inhibiting the enzyme from executing its own normal functions.

Solari believes this is an important biochemical observation because the virus needs the enzyme to assemble its own protein coat that encloses the virus's genetic material.

“What we found is if we block the addition of this fat, the coat doesn’t assemble so the virus doesn’t package its genes into its coat,” he said. “The virus still makes its own genes, it makes the coat, but the coat can’t assemble so the virus can’t replicate – you actually don’t make infectious particles.”

The observed molecules, when bounded create the compound of interest, is believed to completely block the ability of the virus to replicate, and remarkably regardless of when the compound was added whether it is an hour before, an hour after or around the same time as the cells are infected. Furthermore, the addition of the compound in treating infected cells remains effective for up to three hours after infection. This particular approach was studied to inhibit the replication of other viruses that are categorized under the same family as rhinovirus – including polio and foot-and-mouth disease (those that cause polio and foot-and-mouth disease).

Although the compound developed by investigators is successful in treating the common cold, Solari believes there is still a long journey for a cure as the drug will need to undergo many steps beyond the testing of human cells grown on a petri dish. These steps include revolutionizing its development and optimizing the drug's efficacy before its official use as a medicine.

 Computer artwork of the human rhinovirus. Photograph: Alamy Stock Photo

“We haven’t done any animal studies, and we obviously haven’t done any studies in humans, so I can’t tell you formally what the animal toxicity of this compound is,” explains. Additionally, it is unclear on how this particular approach may work by the time symptoms of the common cold appear, which on average are a few days after infection.

“There is a still a long way before this becomes a medicine."

Even if the compound succeeds in passing clinical trials for the common cold, its development will most likely be restricted to only those with respiratory complications such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.

“Rhinovirus, the common cold virus, in healthy people is pretty trivial – you have the runny nose, you have a bit of a temperature, you don’t feel well for two or three days, but you get over it,” states Solari.

Sources: Nature Chemistry, The Guardian

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 14, 2020
APR 14, 2020
Personalized Treatments for Patients with Diabetes and Heart Disease
Often, people who have Type 2 diabetes are at an increased risk for cardiovascular disease. This is because they are usu ...
APR 15, 2020
Chemistry & Physics
APR 15, 2020
Could this drug help people with SAD?
Have you ever been sad in the winter? If so, you’re not alone. Medaka fish feel it too. Seasonal affective disorde ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Overcoming Multi-Drug Resistance in Cancer
Resistance to chemotherapeutic use in caner patients is something that is inevitable. Continued resistance to these drug ...
APR 28, 2020
APR 28, 2020
Is a multi-cancer detection blood test safe for women?
Earlier detection is essential in order to reduce deaths caused by cancer. A new study, DETECT-A (Detecting cancers Earl ...
MAY 07, 2020
MAY 07, 2020
Yet Another Cancer Linked Tyrosine Kinase
In a cell, there are tens of thousands of individual components. Each component has a specific activity or role that the ...
MAY 06, 2020
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
Loading Comments...